Lonidamine as a potentiating agent of the FAC regimen in the treatment of advanced breast cancer. Results of a multicentric randomized clinical study

F. Calabresi, P. Marolla, L. Di Lauro, C. G. Curcio, G. Paoletti, A. Lombardi, D. Giannarelli, P. Ballatore, C. M. Foggi, M. Di Palma, R. Stolfi, E. Cortesi

Research output: Contribution to journalArticlepeer-review

Abstract

A total of 265 patients with metastatic breast cancer were included in a multicentric randomized clinical study with the FAC with or without lonidamine (LND). Objective clinical responses (CR+PR) were observed in 46.7% of the FAC-treated patients (group A) and in 62.1% of the FAC+LND-treated patients (group B) (p = 0.002). Time to progression was 6.3 versus 9.2 months (p = 0.003) and median survival 17.9 versus 18.7 months (N.S.) but in the postmenopausal subgroup patients the median survival was 14.8 versus 18.9 months (p 0.018) for group A versus B, respectively. Group B patients showed no significant increase of toxicity, except for myalgia (WHO grade ≥2 in 24.8% of the LND-heated patients) and epigastralgia (WHO grade ≥2 in 15.0% of the LND-treated patients). These results demonstrate that LND can potentiate the FAC regimen and suggest the need for further investigations of LND combined with other polychemotherapy regimens in breast cancer.

Original languageEnglish
Pages (from-to)753-760
Number of pages8
JournalInternational Journal of Oncology
Volume4
Issue numberSUPPL.
Publication statusPublished - 1994

Keywords

  • advanced breast cancer
  • FAC chemotherapy
  • lonidamine
  • potentiation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Lonidamine as a potentiating agent of the FAC regimen in the treatment of advanced breast cancer. Results of a multicentric randomized clinical study'. Together they form a unique fingerprint.

Cite this